BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference

Wednesday, January 25, 2017 Corporate News
Email Print This Page Comment
Font : A-A+

LYNBROOK, N.Y., Jan. 24, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company

that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced
that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference on Tuesday, January 31, 2017 at 1:00 p.m. ET in Boca Raton, FL.   

A live webcast of the presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or at http://noble.mediasite.com/mediasite/Play/54e0c32b74d8426fbd52bfa93af7bc5f1d.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe and Australia. Swedish Orphan Biovitrum AB (Sobi) has marketing rights for Xiapex® (the European tradename for XIAFLEX) in Europe and certain Eurasian countries and Asahi Kasei Pharma Corporation (Asahi) has marketing rights in Japan. Sobi is selling Xiapex in Europe for the treatment of Dupuytren's contracture and Peyronie's disease and Asahi is selling XIAFLEX for the treatment of Dupuytren's contracture in Japan. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of CCH for uterine fibroids and plans to initiate clinical development in the first quarter of 2017. For more information, please visit www.biospecifics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-noblecon13---noble-capital-markets-thirteenth-annual-investor-conference-300395992.html

SOURCE BioSpecifics Technologies Corp.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook